Literature DB >> 7526568

Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.

L B Tabatabai1, G W Pugh.   

Abstract

Three peptides, peptide 1 (GGDNYSDKPEPLGG), peptide 2 (LAEIKQRSLMVHGG) and peptide 3 (GGAPGEKDGKIVPAG), were synthesized based on the amino acid sequence of Brucella abortus Cu-Zn superoxide dismutase. These peptides were selected on the basis of their predicted hydrophilicity, flexibility and antigenicity profiles. The three peptides, singly or in combination, with or without the adjuvant monophosphoryl lipid A were administered to Balb/c mice as vaccines for brucellosis. The protective and immune responses induced by the peptide vaccines after challenge exposure to virulent B. abortus strain 2308 were compared to those obtained with salt-extractable proteins (BCSP) vaccine prepared from B. abortus strain 19, recombinant B. abortus Cu-Zn superoxide dismutase (rSOD) vaccine and non-vaccinated mice. Mice vaccinated with 30 micrograms of peptide 3 plus 50 micrograms monophosphoryl lipid A afforded two logs of protection (reduction in log10 colony-forming units compared with control mice) and one log of protection when given without monophosphoryl lipid A, whereas 5 micrograms of the salt-extractable proteins afforded three logs of protection. The rSOD and peptides 1 and 2 given with or without monophosphoryl lipid A afforded no protection. Superoxide dismutase-specific IgG antibody was present in postchallenge sera only if BCSP was present in the vaccine. Peptide-specific IgG antibodies were present in postchallenge sera of mice, and antibody concentrations were generally enhanced when monophosphoryl lipid A was included in the vaccine. The overall results with the peptide vaccines suggest that peptide 3 probably contains a specific sequence preferentially recognized by the cellular immune system leading to modulation of immune response mechanisms responsible for decreasing splenic infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526568     DOI: 10.1016/0264-410x(94)90035-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

Review 1.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

2.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice.

Authors:  Shailendra Kumar Verma; Shikha Jain; Subodh Kumar
Journal:  World J Microbiol Biotechnol       Date:  2012-04-22       Impact factor: 3.312

4.  Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus.

Authors:  R Vemulapalli; S Cravero; C L Calvert; T E Toth; N Sriranganathan; S M Boyle; O L Rossetti; G G Schurig
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godfroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.

Authors:  Purushottam Kaushik; Dhirendra K Singh; S Vinoth Kumar; Ashok K Tiwari; Gunjan Shukla; Shanker Dayal; Pallav Chaudhuri
Journal:  Vet Res Commun       Date:  2009-12-16       Impact factor: 2.459

8.  Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51.

Authors:  R Vemulapalli; A J Duncan; S M Boyle; N Sriranganathan; T E Toth; G G Schurig
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice.

Authors:  Angel A Oñate; Sandra Céspedes; Alex Cabrera; Rodolfo Rivers; Andrés González; Carola Muñoz; Hugo Folch; Edilia Andrews
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.